医药魔方 / 最新资讯 / 正文

默沙东2018财报:Keytruda反超Opdivo突破$70亿,宫颈癌疫苗激增近40%

医药魔方 医药魔方 来源:医药魔方
2019-02-02
默沙东 财报
原文

2月1日,默沙东公布2018年业绩,全年实现总收入422.94亿美元,增长5%,其中制药业务收入376.89亿美元(+6%),动物保健业务42.12亿美元(+9%)。2018年默沙东研发总投入97.52亿美元,占收入比重23.1%,相比2017年下降6%。


默沙东最受关注的产品当属Keytruda。经过4年的苦苦较量之后,Keytruda凭借肺癌领域积累的巨大优势上演了业绩反超的好戏,2018年达到惊人的71.71美元。尤其是全年88%的增幅让Opdivo(+36%)相形失色。Opdivo和Keytruda今年将双双进入全球TOP10药物排行榜,而且按这种趋势,Opdivo的2019年销售额将突破100亿美元。



默沙东另一款明星产品是宫颈癌疫苗Gardasil 9。随着中国市场巨大需求的释放,Gardasil 9在中国出现一苗难求的景象。受制于产能原因,Gardasil 9的2018年的增幅只有37%,销售额则达到了31.51亿美元。



表现比较惨的产品是丙肝药Zepatier,从2017年的16.6亿美元直接跌到4.55亿美元,让默沙东也品尝了一下坐电梯的滋味。另外就是受生物类似物困扰的Remicade,2018年也只有5.82亿美元进账,跌幅31%。


默沙东跟阿斯利康达成了PARP抑制剂奥拉帕利的合作开发联盟,与卫材达成了仑伐替尼的合作开发联盟,2018年从这两个药品身上也分别获得了1.87和1.49亿美元的联盟合作收入。


机器翻译

On February 1, Merck announced its 2018 results, bringing revenue to 422.$9.4 billion, a 5% increase, of which pharmaceutical revenue was 376. 5%.$8.9 billion (+ 6%), Animal Health Business 42.$1.2 billion (+ 9%).The total R & D investment of Merck in 2018 is 97.$5.2 billion, as a share of revenue 23.1%, down 6% from 2017.

The most concerned product of Merck is Keytruda.After four years of struggling, Keytruda has staged a stunning 71.71 dollars.In particular, the 88% year-round increase disfigured Opdivo (+ 36%).Both Opdivo and Keytruda will be on the top 10 global drug rankings this year, and by this trend, Opdivo will have sales of more than $10 billion in 2019.

Another star product from Merck is the cervical cancer vaccine Gardasil 9.Gardasil 9 has emerged in China as the release of huge demand from the Chinese market.Gardasil 9's 2018 growth is only 37%, and sales are up 31.$5.1 billion.

$600 million fell directly to 4.For $5.5 billion, it also gave Merck a taste of the elevator.The other is Remicade, which is plagued by biological analogues, and has only 5.$8.2 billion, down 31%.

Merck and AstraZeneca reached a cooperative development alliance for the PARP inhibitor olaparib, and Eisai reached a cooperative development alliance for envatinib, which was also obtained from these two drugs respectively in 2018.87 and $149 million in coalition revenue.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号